Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech ( (ONCY) ) just unveiled an update.
Oncolytics Biotech announced updates on the GOBLET trial, which evaluates pelareorep in gastrointestinal cancers. The trial is expanding to U.S. sites, with Northwestern University among the expected participants. The study has shown promising early efficacy signals, particularly in difficult-to-treat tumors like SCAC and mPDAC. Oncolytics aims to leverage clinical data to obtain regulatory clarity and position pelareorep as a foundational immunotherapy, potentially impacting treatment options for patients in need.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, as well as other gastrointestinal tumors.
Average Trading Volume: 1,195,205
Technical Sentiment Signal: Buy
Current Market Cap: $125.5M
See more insights into ONCY stock on TipRanks’ Stock Analysis page.